<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39365115</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000006444</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Adults who were hospitalized for COVID-19.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Newly initiated on baricitinib or tocilizumab.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0 ± 15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85-0.98) and hospital (OR, 0.88; 95% CI, 0.82-0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90-0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75-0.99), although no difference in ICU length of stay was noted between the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.</AbstractText><CopyrightInformation>Copyright © 2024 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patanwala</LastName><ForeName>Asad E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0003-3999-4703</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xuya</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hills</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Medical Research Institute of New Zealand, Wellington, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Alisa M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McArthur</LastName><ForeName>Colin J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Auckland City Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>G Caleb</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Hemalkumar B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Covid Cohort Collaborative (N3C) Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Dr. Higgins is supported by a National Health and Medical Research Council Investigator Grant (GNT2008447). Dr. Mehta is supported by the National Institute on Aging (1K01AG070329). The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graves</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anzalone</LastName><ForeName>Alfred Jerrod</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olex</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Southerland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharathkumar</LastName><ForeName>Anjali A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendricks</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Brijesh</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward-Caviness</LastName><ForeName>Cavin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madlock-Brown</LastName><ForeName>Charisse</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillon</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chunlei</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takemoto</LastName><ForeName>Cliff</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Housman</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichmann</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzotti</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Don</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudreau</LastName><ForeName>Eilis</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zampino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>Emily Carlson</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>French</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koraishy</LastName><ForeName>Farrukh M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mariona</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prior</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sokos</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidky</LastName><ForeName>Hythem</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayanga</LastName><ForeName>J W Awori</ForeName><Initials>JWA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pincavitch</LastName><ForeName>Jami</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Jaylyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Jeremy Richard</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Islam</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ge</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagnier</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loomba</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathew</LastName><ForeName>Jomol</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutter</LastName><ForeName>Joni L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guinney</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starren</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowley</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradwell</LastName><ForeName>Katie Rebecca</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walters</LastName><ForeName>Kellie M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gersing</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cato</LastName><ForeName>Kenrick Dwain</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Northington</LastName><ForeName>Lavance</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pyles</LastName><ForeName>Lee Allan</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Misquitta</LastName><ForeName>Leonie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cottrell</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portilla</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deacy</LastName><ForeName>Mariam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Marshall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emmett</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Mary Morrison</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Meredith</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temple-O'Connor</LastName><ForeName>Meredith</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurilla</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safdar</LastName><ForeName>Nasia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garbarini</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharafeldin</LastName><ForeName>Noha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadan</LastName><ForeName>Ofer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgoon</LastName><ForeName>Penny Wung</ForeName><Initials>PW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Philip R O</ForeName><Initials>PRO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawa</LastName><ForeName>Randeep</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erwin-Cohen</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Rena</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamaleswaran</LastName><ForeName>Rishi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurley</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pyarajan</LastName><ForeName>Saiju</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Sam G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozzette</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallipattu</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vedula</LastName><ForeName>Satyanarayana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neil</LastName><ForeName>Shawn T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Setoguchi</LastName><ForeName>Soko</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callahan</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Umit</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Usman</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Valery</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kibbe</LastName><ForeName>Warren A</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Wenndy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beasley</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hillegass</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39365115</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000006444</ArticleId><ArticleId IdType="pii">00003246-990000000-00386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institutes of Health: COVID-19 Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/. Accessed May 10, 2023</Citation></Reference><Reference><Citation>National Clinical Evidence Taskforce: Evidence-Based Clinical COVID-19 Guidelines. Available at: https://clinicalevidence.net.au/covid-19/. Accessed May 10, 2023</Citation></Reference><Reference><Citation>Banerjee S, Biehl A, Gadina M, et al.: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and Future Prospects. Drugs 2017; 77:521–546</Citation></Reference><Reference><Citation>Ely EW, Ramanan AV, Kartman CE, et al.; COV-BARRIER Study Group: Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial. Lancet Respir Med 2022; 10:327–336</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637–1645</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022; 400:359–368</Citation></Reference><Reference><Citation>Investigators R-C, Gordon AC, Mouncey PR, et al.: Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021; 384:1491–1502</Citation></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al.; ACTT-2 Study Group Members: Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384:795–807</Citation></Reference><Reference><Citation>Karampitsakos T, Papaioannou O, Tsiri P, et al.: Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: An open label, randomized controlled trial. Clin Microbiol Infect 2023; 29:372–378</Citation></Reference><Reference><Citation>Conroy GM, Bauer SR, Pallotta AM, et al.: Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study. Pharmacotherapy 2023; 44:28–38</Citation></Reference><Reference><Citation>Peterson JH, Paranjape NS, Grundlingh N, et al.: Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19. Crit Care Med 2023; 51:337–346</Citation></Reference><Reference><Citation>Sunny S, Tran A, Lee J, et al.: Comparison of tocilizumab vs baricitinib in clinical outcomes among hospitalized patients with COVID-19: Experience from a public hospital system in New York City. Open Forum Infect Dis 2023; 10:ofad426</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al.; STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370:1453–1457</Citation></Reference><Reference><Citation>National-COVID-Cohort-Collaborative: COVID-19 Phenotype Documentation, Version 4.0 (last updated 3/11/2022). Available at: https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype. Accessed May 10, 2023</Citation></Reference><Reference><Citation>Agency for Health Care Research and Quality: Healthcare Cost and Utilization Project. National Inpatient Sample Description of Data Elements. Available at: https://www.hcup-us.ahrq.gov/db/vars/race/nisnote.jsp. Accessed May 10, 2023</Citation></Reference><Reference><Citation>Quan H, Li B, Couris CM, et al.: Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676–682</Citation></Reference><Reference><Citation>Andersen KM, Bates BA, Rashidi ES, et al.; National COVID Cohort Collaborative Consortium: Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol 2022; 4:e33–e41</Citation></Reference><Reference><Citation>National Kidney Foundation: How to Classify CKD. Available at: https://www.kidney.org/professionals/explore-your-knowledge/how-to-classify-ckd. Accessed June 21, 2023</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention: Healthcare-Associated Infections (HAIs). Available at: https://www.cdc.gov/hai/infectiontypes.html.Accessed May 10, 2023</Citation></Reference><Reference><Citation>Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083–3107</Citation></Reference><Reference><Citation>Nguyen TL, Collins GS, Spence J, et al.: Double-adjustment in propensity score matching analysis: Choosing a threshold for considering residual imbalance. BMC Med Res Methodol 2017; 17:78</Citation></Reference><Reference><Citation>Sweeney DA, Tuyishimire B, Ahuja N, et al.: Baricitinib treatment of coronavirus disease 2019 is associated with a reduction in secondary infections. Open Forum Infect Dis 2023; 10:ofad205</Citation></Reference><Reference><Citation>Forsberg J, Bedard E, Mahmoud SH: Bioavailability of orally administered drugs in critically ill patients. J Pharm Pract 2022; 36:967–979</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>